Menumenu
  • Home
  • Women's health and paediatrics Publications

Women's health and paediatrics Publications

Women's health and paediatrics Publications

  • Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes.Abstract

    OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 1years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System

    Ahmadizar F, Souverein PC, Arets HG, deBoer A, Maitland-van der Zee AH. Pediatr Pulmonol. 2016 Nov; 51 1113-1121.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study.Abstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 433-40.
  • Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands.Abstract

    OBJECTIVE: To assess the trends in the incidence and prevalence rates of type 1 diabetes (T1D) among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted in the Dutch PHARMO record linkage system (19982011). All children and adolescents aged

    FazeliFarsani S, Souverein PC, van der Vorst MM, Knibbe CA, Herings RM, deBoer A, Mantel-Teeuwisse AK. Pediatr Diabetes. 2016 Feb; 17 44-52.
  • Use of oral contraceptives in three European countries: a population-based multi-database study.Abstract

    OBJECTIVES: The aim of the study was to assess the prevalence of oral contraceptive (OC) use, user characteristics and prescribing patterns by accessing health care databases of three European countries. METHODS: A retrospective study was performedfrom 2009 to 2010 in three general practice (GP) databases from the Netherlands, UK and Italy and in one database of linked pharmacy and hospitalisation data in the Netherlands

    Bezemer ID, Verhamme KM, Gini R, Mosseveld M, Rijnbeek PR, Trifiro G, Sturkenboom MC, Penning-van Beest FJ, Herings RM. Eur J Contracept Reprod Health Care. 2016 Feb; 21 81-7.
  • Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children.Abstract

    BACKGROUND: Non-adherence to inhaled corticosteroids (ICSs) is a major risk factor for poor asthma control in children. However, little is known about the effect of adherence to ICS on the incidence of asthma exacerbations. The objective of this stdy was to examine the effect of poor adherence to ICS on the risk of exacerbations in children with asthma

    Vasbinder EC, Belitser SV, Souverein PC, van Dijk L, Vulto AG, van den Bemt PM. Patient Prefer Adherence. 2016 10 531-8.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.Abstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 927-32.
  • Trends in paediatric macrolide use in five European countries-a population-based study.Abstract

    PURPOSE: The study aims to analyse overall as well as subgroup-specific outpatient paediatric macrolide use in five European countries, including time trends of macrolide prescription rates, and to provide potential targets for future interventionsaiming to promote judicious macrolide use. METHODS: Macrolide prescription rates per 1000 person years to paediatric outpatients (

    Holstiege J, Ender s D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, Trifiro G, Garbe E. Eur J Clin Pharmacol. 2015 Aug; 71 991-9.
  • Chronic comorbidities in children with type 1 diabetes: a population-based cohort study.Abstract

    OBJECTIVE: To determine the incidence of chronic comorbidities among children with type 1 diabetes (T1D) and to compare incidences with a group of children without diabetes. DESIGN: Population-based cohort study. SETTING: Dutch PHARMO database (199-2010). PATIENTS: All patients (<19 years old) with T1D between 1999 and 2009 (T1D cohort) and a group of age- and sex-matched (ratio: 1-4) children without diabetes (reference cohort)

    FazeliFarsani S, Souverein PC, van der Vorst MM, Knibbe CA, deBoer A, Mantel-Teeuwisse AK. Arch Dis Child. 2015 Aug; 100 763-8.
  • The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.Abstract

    AIM: Electronic healthcare record (EHR)-based surveillance systems are increasingly being developed to support early detection of safety signals. It is unknown what the power of such a system is for surveillance among children and adolescents. In tis paper we provide estimates of the number and classes of drugs, and incidence rates (IRs) of events, that can be monitored in children and adolescents (0-18 years)

    deBie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifiro G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Peder sen L, Stricker BH, van der Lei J, Sturkenboom MC, consortium Eu-Adr. Br J Clin Pharmacol. 2015 Aug; 80 304-14.
  • Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands.Abstract

    AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All paients younger than 20 years old with at least one OAD dispensing were identified

    FazeliFarsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, deBoer A, Mantel-Teeuwisse AK. Br J Clin Pharmacol. 2015 Aug; 80 294-303.